Helius Medical Technologies (FRA:26H) ROCE % : -134.18% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Helius Medical Technologies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Helius Medical Technologies's annualized ROCE % for the quarter that ended in Dec. 2023 was -134.18%.

Helius Medical Technologies ROCE % Historical Data

The historical data trend for Helius Medical Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helius Medical Technologies ROCE % Chart

Helius Medical Technologies Annual Data

Trend

Mar14

Mar15

Mar16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-296.81

-254.88

-237.36

-113.39

-113.80

Helius Medical Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-62.46	-111.14	-120.69	-145.06	-134.18

Helius Medical Technologies ROCE % Calculation

Helius Medical Technologies's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-11.251	/	( ( (16.319 - 1.877)	+	(7.054 - 1.723) )	/ 2 )
	=	-11.251	/	( (14.442	+	5.331)	/ 2 )
	=	-11.251	/	9.8865
	=	-113.80 %

Helius Medical Technologies's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-8.24	/	( ( (8.296 - 1.345)	+	(7.054 - 1.723) )	/ 2 )
	=	-8.24	/	( ( 6.951	+	5.331 )	/ 2 )
	=	-8.24	/	6.141
	=	-134.18 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Helius Medical Technologies (FRA:26H) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Helius Medical Technologies ROCE % Related Terms

Thank you for viewing the detailed overview of Helius Medical Technologies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Helius Medical Technologies (FRA:26H) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Helius Medical Technologies Inc (FRA:26H) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

HSDT:USA

Address

642 Newtown Yardley Road, Suite 100, Newtown, PA, USA, 18940

Website

https://www.heliusmedical.com

Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, non-implantable medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.

Helius Medical Technologies (FRA:26H) Headlines

No Headlines